
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1041 | 972 | 991 | 1155 | 1484 | 1971 |
Fund Return | 4.15% | -2.79% | -0.86% | 4.94% | 8.22% | 7.02% |
Place in category | 102 | 93 | 126 | 65 | 73 | 52 |
% in Category | 55 | 49 | 70 | 34 | 43 | 46 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Stock Market Ins Pls | 730.53B | 1.13 | 11.51 | - | ||
Vanguard 500 Index Admiral | 568.34B | 1.44 | 12.50 | 12.94 | ||
Vanguard Total Stock Market Admiral | 407.95B | 1.12 | 11.49 | 12.30 | ||
Vanguard Total Intl Stock Index Inv | 209.79B | 5.17 | 4.34 | 4.95 | ||
Vanguard 500 Index Institutional Se | 207.17B | 1.44 | 12.54 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
T. Rowe Price Health Sciences | 6.68B | 4.25 | 3.25 | 8.01 | ||
Fidelity Select Health Care | 6.74B | 2.50 | 3.68 | 7.60 | ||
Vanguard Health Care Inv | 6.25B | 4.15 | 4.89 | 6.97 | ||
T. Rowe Price Health Sciences I | 4.69B | 4.29 | 3.39 | - | ||
Fidelity Select Medical Equip & Sy | 5B | 3.79 | 0.44 | 11.12 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.69 | 738.21 | -6.45% | |
UnitedHealth | US91324P1021 | 7.83 | 525.05 | -2.85% | |
AstraZeneca | GB0009895292 | 5.73 | 10,808.0 | -5.13% | |
Merck&Co | US58933Y1055 | 5.28 | 81.47 | -5.70% | |
Novo Nordisk B | DK0062498333 | 4.49 | 432.0 | -5.45% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review